Loading...
Androgen-deprivation therapy (ADT) has been the gold standard for men with newly diagnosed metastatic prostate cancer for more than 6 decades. The median overall survival for men who begin hormonal therapy for metastatic prostate cancer is about 24 to 36 months; however, duration of response and survival is variable.
Investigators from the Southwest Oncology Group (SWOG) used data from an ongoing phase III study of metastatic prostate cancer (designed to determine whether survival is equivalent with intermittent ADT or continuous ADT). In the trial, all men receive 7 months of therapy with a gonadotropin-releasing hormone (GnRH)–agonist plus an antiandrogen drug. At the end of this induction period, men with stable or declining prostate-spec…